Skip to main content
Erschienen in: Internal and Emergency Medicine 2/2020

10.02.2020 | CE-Systematic reviews and meta-analysis

Acute kidney injury and vancomycin/piperacillin/tazobactam in adult patients: a systematic review

verfasst von: Tiziana Ciarambino, Orazio Valerio Giannico, Amalia Campanile, Paolo Tirelli, Ombretta Para, Giuseppe Signoriello, Mauro Giordano

Erschienen in: Internal and Emergency Medicine | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

The aim of this systematic review was to assess AKI (acute kidney injury) in adult patients, treated with vancomycin (V) + piperacillin/tazobactam (PT) compared to V monotherapy. Studies were found in Pubmed, Web of Science and Scopus databases. Articles not in English, pediatric studies and case reports were excluded. A study is eligible for inclusion if the adjusted Odds ratio (aOR) for AKI in V + PT compared to V monotherapy groups, could be extracted or determined from available data. Six retrospective cohort studies were eligible for inclusion criteria and so they were included in the analysis. All studies separately showed a significant higher risk of developing AKI (OR > 1, p < 0.05) in V + PT group compared to V monotherapy group. Considering the methodological difference of included studies, a random effect model was preferred. The model showed a pooled significant higher risk of developing AKI [OR 2.77 (95% CI 1.94, 3.96), p < 0.0001] in V + PT group compared to V group. Association of V and PT appears to be associated with a greater risk of AKI compared to V in monotherapy. These results may serve as the impetus for further evaluation into true mechanisms behind this additive nephrotoxic effect and its potential implications on mortality.
Literatur
1.
Zurück zum Zitat Magill SS, Edwards JR, Beldavs ZG et al (2011) Emerging infections program healthcare- associated infections and antimicrobial use prevalence survey team. 2014. prevalence of antimicrobial use in US acute care hospitals. JAMA 312:1438–1446CrossRef Magill SS, Edwards JR, Beldavs ZG et al (2011) Emerging infections program healthcare- associated infections and antimicrobial use prevalence survey team. 2014. prevalence of antimicrobial use in US acute care hospitals. JAMA 312:1438–1446CrossRef
2.
Zurück zum Zitat Gin A, Dilay L, Karlowsky JA et al (2007) Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination. Expert Rev Anti Infect Ther 5(3):365–383CrossRef Gin A, Dilay L, Karlowsky JA et al (2007) Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination. Expert Rev Anti Infect Ther 5(3):365–383CrossRef
3.
Zurück zum Zitat Meaney CJ, Hynicka LM, Tsoukleris MG (2014) Vancomycin-associated nephrotoxicity in adult medicine patients: incidence, outcomes, and risk factors. Pharmacotherapy 34:653–661CrossRef Meaney CJ, Hynicka LM, Tsoukleris MG (2014) Vancomycin-associated nephrotoxicity in adult medicine patients: incidence, outcomes, and risk factors. Pharmacotherapy 34:653–661CrossRef
4.
Zurück zum Zitat Gomes DM, Smotherman C, Birch A et al (2014) Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin–tazobactam or cefepime. Pharmacotherapy 34:662–669CrossRef Gomes DM, Smotherman C, Birch A et al (2014) Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin–tazobactam or cefepime. Pharmacotherapy 34:662–669CrossRef
5.
Zurück zum Zitat Ephraim RKD, Darkwah KO, et al (2016) Assessment of the RIFLE criteria for the diagnosis of acute kidney injury; a retrospective study in South-Western Ghana. BMC Nephrol. 17(1):99. Ephraim RKD, Darkwah KO, et al (2016) Assessment of the RIFLE criteria for the diagnosis of acute kidney injury; a retrospective study in South-Western Ghana. BMC Nephrol. 17(1):99.
6.
Zurück zum Zitat Wells GA, Shea B, O’Connell D, et al. (2011) The Newcastle–Ottawa Scale (nos) for assessing the quality of nonrandomized studies in meta-analysis. Accessed 25 November 2012. Wells GA, Shea B, O’Connell D, et al. (2011) The Newcastle–Ottawa Scale (nos) for assessing the quality of nonrandomized studies in meta-analysis. Accessed 25 November 2012.
7.
Zurück zum Zitat Kim T, Kandiah S, Patel M et al (2015) Risk factors for kidney injury during vancomycin and piperacillin/tazobactam administration, including increased odds of injury with combination therapy. BMC Res Notes 17(8):579CrossRef Kim T, Kandiah S, Patel M et al (2015) Risk factors for kidney injury during vancomycin and piperacillin/tazobactam administration, including increased odds of injury with combination therapy. BMC Res Notes 17(8):579CrossRef
8.
Zurück zum Zitat Rutter WC, Cox JN, Martin CA, Erratum for Rutter et al. (2017) Nephrotoxicity during vancomycin therapy in combination with piperacillin-tazobactam or cefepime. Antimicrob Agents Chemother 61(4) Rutter WC, Cox JN, Martin CA, Erratum for Rutter et al. (2017) Nephrotoxicity during vancomycin therapy in combination with piperacillin-tazobactam or cefepime. Antimicrob Agents Chemother 61(4)
9.
Zurück zum Zitat Anderson CW, Cazares KS, Lustik MB, et al (2017) Vancomycin vs. vancomycin/piperacillin–tazobactam-associated acute kidney injury in non-critically ill patients at a tertiary care military treatment facility. Mil Med 182(9):e1773–e1778. Anderson CW, Cazares KS, Lustik MB, et al (2017) Vancomycin vs. vancomycin/piperacillin–tazobactam-associated acute kidney injury in non-critically ill patients at a tertiary care military treatment facility. Mil Med 182(9):e1773–e1778.
10.
Zurück zum Zitat Balcı C, Uzun Ö, Arıcı M et al (2018) Nephrotoxicity of piperacillin/tazobactam combined with vancomycin: should it be a concern? Int J Antimicrob Agents 52(2):180–184CrossRef Balcı C, Uzun Ö, Arıcı M et al (2018) Nephrotoxicity of piperacillin/tazobactam combined with vancomycin: should it be a concern? Int J Antimicrob Agents 52(2):180–184CrossRef
11.
Zurück zum Zitat Carreno J, Smiraglia T, Hunter C et al (2018) Comparative incidence and excess risk of acute kidney injury in hospitalised patients receiving vancomycin and piperacillin/tazobactam in combination or as monotherapy. Int J Antimicrob Agents 52(5):643–650CrossRef Carreno J, Smiraglia T, Hunter C et al (2018) Comparative incidence and excess risk of acute kidney injury in hospitalised patients receiving vancomycin and piperacillin/tazobactam in combination or as monotherapy. Int J Antimicrob Agents 52(5):643–650CrossRef
12.
Zurück zum Zitat Eberle H, Rogers M, Lee M et al (2018) A comparison of nephrotoxicity in non-intensive care unit medical-surgical patients receiving vancomycin alone versus vancomycin with piperacillin-tazobactam. Infect Dis Clin Pract 26(1):23–26CrossRef Eberle H, Rogers M, Lee M et al (2018) A comparison of nephrotoxicity in non-intensive care unit medical-surgical patients receiving vancomycin alone versus vancomycin with piperacillin-tazobactam. Infect Dis Clin Pract 26(1):23–26CrossRef
13.
Zurück zum Zitat Kalil AC, Metersky ML, Klompas M et al (2016) Management of adults with hospital-acquired and ventilator-associated pneumonia: clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 63:e61–e111CrossRef Kalil AC, Metersky ML, Klompas M et al (2016) Management of adults with hospital-acquired and ventilator-associated pneumonia: clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 63:e61–e111CrossRef
14.
Zurück zum Zitat Hammond DA, Smith MN et al (2017) Systematic review and meta-analysis of acute kidney injury associated with concomitant vancomycin and piperacillin/tazobactam. Clin Infect Dis 64:5CrossRef Hammond DA, Smith MN et al (2017) Systematic review and meta-analysis of acute kidney injury associated with concomitant vancomycin and piperacillin/tazobactam. Clin Infect Dis 64:5CrossRef
15.
Zurück zum Zitat Elyasi S, Khalili H, Dashti-Khavidaki S, et al (2012). Vancomycin- induced nephrotoxicity: mechanism, incidence, risk factors, and special populations. A literature review. Eur J Clin Pharmacol 68:1243–1255. Elyasi S, Khalili H, Dashti-Khavidaki S, et al (2012). Vancomycin- induced nephrotoxicity: mechanism, incidence, risk factors, and special populations. A literature review. Eur J Clin Pharmacol 68:1243–1255.
16.
Zurück zum Zitat Navalkele B, Pogue JM, Karino S, et al (2016). Risk of acute kidney injury in patients on concomitant vancomycin and piperacillin/tazobactam compared to those on vancomycin and cefepime. Clin Infect Dis. Navalkele B, Pogue JM, Karino S, et al (2016). Risk of acute kidney injury in patients on concomitant vancomycin and piperacillin/tazobactam compared to those on vancomycin and cefepime. Clin Infect Dis.
17.
Zurück zum Zitat Hammond DA, Smith MN, Li C, et al (2017). Systematic review and meta-analysis of acute kidney injury associated with concomitant vancomycin and piperacillin/tazobactam. Clin Infect Dis 64(5):666–674. Hammond DA, Smith MN, Li C, et al (2017). Systematic review and meta-analysis of acute kidney injury associated with concomitant vancomycin and piperacillin/tazobactam. Clin Infect Dis 64(5):666–674.
18.
Zurück zum Zitat Ragab AR, AL Mazroua MK, Al Harony MK (2013) Incidence and predisposing factors of vancomycin-induced nephrotoxicity in children. Infect Dis Ther 2:37–46CrossRef Ragab AR, AL Mazroua MK, Al Harony MK (2013) Incidence and predisposing factors of vancomycin-induced nephrotoxicity in children. Infect Dis Ther 2:37–46CrossRef
Metadaten
Titel
Acute kidney injury and vancomycin/piperacillin/tazobactam in adult patients: a systematic review
verfasst von
Tiziana Ciarambino
Orazio Valerio Giannico
Amalia Campanile
Paolo Tirelli
Ombretta Para
Giuseppe Signoriello
Mauro Giordano
Publikationsdatum
10.02.2020
Verlag
Springer International Publishing
Erschienen in
Internal and Emergency Medicine / Ausgabe 2/2020
Print ISSN: 1828-0447
Elektronische ISSN: 1970-9366
DOI
https://doi.org/10.1007/s11739-020-02287-2

Weitere Artikel der Ausgabe 2/2020

Internal and Emergency Medicine 2/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.